Why Endeavor Health Refuses to Silo Its Value-Based Care Strategy
Lakshmi Halasyamani, chief clinical officer at Endeavor Health, thinks value-based care isn't really about payment models. To her, this work centers on understanding patients' clinical, social and financial circumstances well enough to make care plans that actually work for their lives.
Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders
Argenx’s first acquisition is the buyout of Forte Biosciences, a company with a lead drug that has early clinical validation in celiac disease and vitiligo. Argenx executives say this antibody complements its blockbuster product Vyvgart, offering a different mechanism of action but similar pipeline-in-a-product potential.
Prior Authorization Is Draining Revenue: Why Automation Has Become a Strategic Imperative
When staff are overextended and patients face delays or abandon care, the issue is no longer a narrow administrative burden. It becomes a business, financial, and access challenge that demands a different operating model.
How AI Inside Clinical Workflows Is Unlocking Patient Throughput
The question is not whether the technology is impressive. The question is whether it shows up at the right time, with the right information, inside the workflow where the decision is being made. Anything else is just another report.
presented by
AI Readiness Starts with Solving Healthcare’s Data Fragmentation Problem
On a recent webinar sponsored by Verato, panelists from SCAN Health Group and the Alliance of Community Health Plans discussed how their organizations are meeting the moment.